-
Product Insights
NewNet Present Value Model: MacroGenics Inc’s Vobramitamab Duocarmazine
Empower your strategies with our Net Present Value Model: MacroGenics Inc's Vobramitamab Duocarmazine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MacroGenics Inc’s Tebotelimab
Empower your strategies with our Net Present Value Model: MacroGenics Inc's Tebotelimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: MacroGenics Inc’s MGC-018
Empower your strategies with our Net Present Value Model: MacroGenics Inc's MGC-018 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of MacroGenics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of MacroGenics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Izeltabart Tapatansine in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izeltabart Tapatansine in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Izeltabart Tapatansine in Solid Tumor Drug Details: Izeltabart tapatansine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-534 in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PM-534 in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PM-534 in Castration-Resistant Prostate Cancer (CRPC) Drug Details: PM-534 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OTA-201 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OTA-201 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OTA-201 in Refractory Multiple Myeloma Drug Details: OTA-201 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Sarcomas Drug Details: AGEN-2373 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PF-07275315 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07275315 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07275315 in Atopic Dermatitis (Atopic Eczema) Drug Details: PF-07275315 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGD-024 in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGD-024 in Systemic Mastocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGD-024 in Systemic Mastocytosis Drug Details: MGD-024 is under development for the...